Donanemab in Early Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A hallmark of Alzheimer's disease is the accumulation of amyloid-β (Aβ) peptide. Donanemab, an antibody that targets a modified form of deposited Aβ, is being investigated for the treatment of early Alzheimer's disease. METHODS: ), the Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living Inventory (ADCS-iADL), and the Mini-Mental State Examination (MMSE), as well as the change in the amyloid and tau burden on PET. RESULTS: A total of 257 patients were enrolled; 131 were assigned to receive donanemab and 126 to receive placebo. The baseline iADRS score was 106 in both groups. The change from baseline in the iADRS score at 76 weeks was -6.86 with donanemab and -10.06 with placebo (difference, 3.20; 95% confidence interval, 0.12 to 6.27; P = 0.04). The results for most secondary outcomes showed no substantial difference. At 76 weeks, the reductions in the amyloid plaque level and the global tau load were 85.06 centiloids and 0.01 greater, respectively, with donanemab than with placebo. Amyloid-related cerebral edema or effusions (mostly asymptomatic) occurred with donanemab. CONCLUSIONS: In patients with early Alzheimer's disease, donanemab resulted in a better composite score for cognition and for the ability to perform activities of daily living than placebo at 76 weeks, although results for secondary outcomes were mixed. Longer and larger trials are necessary to study the efficacy and safety of donanemab in Alzheimer's disease. (Funded by Eli Lilly; TRAILBLAZER-ALZ ClinicalTrials.gov number, NCT03367403.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The phase 3 trial of donanemab, monoclonal antibody that target Aβ plaques, fibrils, soluble protofibrils, and oligomeric Aβ species all targeting A β plaques, required p eople with early AD to have both positive amyloid PET and tau-PET, further dividing participants into low and intermediate/high positive tau burden groups.(464)”
From Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission (2024) · cites this paper as [464]
In the citing paper
“These interventions have demonstrated a modest capacity to reduce cognitive decline in select patient subgroups, but are associated with the risk of side effects, including brain swelling and microhemorrhages.”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Mintun et al. 2021
In the citing paper
“These interventions have demonstrated a modest capacity to reduce cognitive decline in select patient subgroups, but are associated with the risk of side effects, including brain swelling and microhemorrhages.”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Mintun et al. 2021
In the citing paper
“The first therapies for AD targeting the removal of amyloid are now being approved with modest positive outcomes, although associated with several side effects (Sims et al. 2023; Mintun et al. 2021; Van Dyck et al. 2023).”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Mintun et al. 2021
In the citing paper
“One response to these problems has been the design of clinical instruments that purport to be able to reveal treatment effects with greater sensitivity: for example, the iADRS 83 or the preclinical Alzheimer cognitive composite 96 .”
From The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics (2022) · cites this paper as [83]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Self-citationThe antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Self-citationTwo Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Self-citationMasters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., & Cummings, J. L. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.56 · Cited by 1,853
A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738
Synergy between amyloid-β and tau in Alzheimer’s disease
Busche, M. A., & Hyman, B. T. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0687-6 · Cited by 1,242
Cited by
Items 901–1,000 of 1,008
Hou, Z., Sun, A., Li, Y., Song, X., Liu, S., Hu, X., Luan, Y., Guan, H., He, C., Sun, Y., et al. (2024) · Mediators of Inflammation · doi:10.1155/2024/7709277 · Cited by 7
“Clinically, the diagnostic methods of cognitive disorders mainly include the MoCA, ADL, CDR, HIS, and other scales [17, 18]; magnetic resonance imaging (MRI) [19, 20]; and 18 F-labeled deoxyglu-cose PET ( 18 FDG-PET) technology [21].”
Li, Y., Zhang, X., Zhao, H., Wang, Y., Zhang, D., Wang, X., Dong, R., Yan, X., Wu, J., Sui, Y., et al. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00149 · Cited by 6
Kang, D. W., Wang, S., Um, Y. H., Kim, S., Kim, T., Kim, D., Lee, C. U., & Lim, H. K. (2024) · Scientific Reports · doi:10.1038/s41598-024-67664-9 · Cited by 5
Boyarko, B., Podvin, S., Greenberg, B., Arnold, S. E., Juanes, A. M., van der Kant, R., Goldstein, L. S. B., Momper, J. D., Bang, A. G., Silverman, J., et al. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00229 · Cited by 9
IsHak, W. W., Meyer, A., Freire, L., Totlani, J., Murphy, N., Renteria, S., Salem, M., Chang, T., Abdelsalam, R., Khan, R., et al. (2024) · PubMed Central · Cited by 8
Yang, Y., Qiu, H., Fan, Y., Zhang, Q., Qin, H., Wu, J., Zhang, X., Liu, Y., Zhou, R., Zhang, Q., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01584-8 · Cited by 8
“Given that only healthy subjects were enrolled with single dose of investigational product (IP) administered in these first-in-human studies, no brain MRI scans were performed to assess ARIAs, which are important AEs associated other anti-Aβ mAbs [7, 9, 12–14].”
BackgroundPredicting regional tau accumulation with machine learning‐based tau‐PET and advanced radiomics
Rathore, S., Higgins, I. A., Wang, J., Kennedy, I. A., Iaccarino, L., Burnham, S. C., Pontecorvo, M. J., & Shcherbinin, S. (2024) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70005 · Cited by 10
“12–14 Multiple recent studies have identified variables such as age, sex, education, apolipoprotein E (APOE)- ε 4 genotype, BIN1 risk allele, cognitive tests, and florbetapir 18F-PET standardized uptake value ratio (SUVr) that are generally available in research settings and are prognostic…”
Self-citationStögmann, E., & Schmidt, R. (2025) · Wiener klinische Wochenschrift · doi:10.1007/s00508-024-02466-7 · Cited by 6
“Recently, phase 3 trials demonstrated for the first time that monoclonal antibodies reduce amyloid deposits and thereby slow the progression of symptoms of the disease [6–11].”
Wu, J., Tang, J., Huang, D., Wang, Y., Zhou, E., Ru, Q., Xu, G., Chen, L., & Wu, Y. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1482947 · Cited by 8
Electrophysiological insights into Alzheimer's disease: A review of human and animal studies
Calvin, K., McNeela, A. M., Osse, A. M. L., Bhasin, G., Ridenour, M., Kinney, J. W., & Hyman, J. M. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105987 · Cited by 8
Autoradiographic comparison between [11C]PiB and [18F]AZD4694 in human brain tissue
Aliaga, A., Therriault, J., Quispialaya, K. M., Aliaga, A., Kunach, P., Macedo, A. C., Hopewell, R., Rahmouni, N., Soucy, J., Massarweh, G., et al. (2025) · EJNMMI Research · doi:10.1186/s13550-025-01216-8 · Cited by 5
Nitrini, R., & Studart-Neto, A. (2025) · Arquivos de Neuro-Psiquiatria · doi:10.1055/s-0045-1808082 · Cited by 6
“3,7,8 Its use was approved by the FDA in 2024, after the TRAILBLAZER-ALZ 2 study.”
Pivtoraiko, V. N., Racic, T., Abrahamson, E. E., Villemagne, V. L., Handen, B. L., Lott, I. T., Head, E., & Ikonomović, M. D. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.728739 · Cited by 7
Mansfield, C. A., Bullok, K. E., Fuhs, J. V., Tockhorn‐Heidenreich, A., Andrews, J. S., DiBenedetti, D. B., Matthews, B. R., Darling, J. C., Sutphin, J., & Hauber, B. (2022) · Patient · doi:10.1007/s40271-022-00576-w · Cited by 7
Imaging Alzheimer’s pathology stage by stage
Malpetti, M., & Joie, R. L. (2022) · Nature Aging · doi:10.1038/s43587-022-00236-6 · Cited by 7
Unfairness to Patients With Alzheimer Disease in Medicare’s Coverage of Antiamyloid Immunotherapy
Stern, A. M., & Selkoe, D. J. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.2131 · Cited by 6
Amyloid-β targeting immunisation in aged non-human primate ( Microcebus murinus )
Trouche, S. G., Boutajangout, A., Asuni, A. A., Fontès, P., Sigurdsson, E. M., Verdier, J., & Mestre‐Francés, N. (2022) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2022.12.021 · Cited by 7
Brandt, N., Wheeler, C., & Courtin, S. O. (2023) · Journal of Gerontological Nursing · doi:10.3928/00989134-20221205-02 · Cited by 6
Clinical Management in Alzheimer’s Disease in the Era of Disease-Modifying Therapies
Guo, M. H., & Vaishnavi, S. (2023) · Current Treatment Options in Neurology · doi:10.1007/s11940-023-00750-x · Cited by 6
Gauthier, S. G., Ismail, Z., Goodarzi, Z., Ng, K. P., & Rosa‐Neto, P. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.72 · Cited by 7
Matsuda, H., & Yamao, T. (2023) · FUKUSHIMA JOURNAL OF MEDICAL SCIENCE · doi:10.5387/fms.2023-08 · Cited by 6
Cantillon, M., Andreasen, N. C., & Prins, N. D. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.2 · Cited by 7
“Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) often increased with ARIA-E and was present in up to 30% of homozygous carriers in donanemab (16) and gantenerumab (17).”
Novel strategies for the fight of Alzheimer’s disease targeting amyloid-β protein
Xie, Y., Wang, Y., Jiang, S., Xiang, X., Wang, J., & Ning, L. (2021) · Journal of drug targeting · doi:10.1080/1061186x.2021.1973482 · Cited by 7
“Another drug called donanemab (LY-3002813) also showed promising therapeutic potential in phase II clinical trials [102,103].”
BackgroundGurunathan, V., Hamre, J. R., Klimov, D. K., & Jafri, M. S. (2021) · Biomolecules · doi:10.3390/biom11101541 · Cited by 6
“Donanemab has shown to improve the composite score for cognition and the ability to perform daily activities in clinical trials and has awarded FDA Breakthrough Therapy designation in June 2021 [8,9].”
BackgroundResultSmith, E. E., Greenberg, S. M., & Black, S. E. (2023) · Cerebral Circulation - Cognition and Behavior · doi:10.1016/j.cccb.2023.100159 · Cited by 7
“More recently, lecanemab has been reported to reduce decline in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) by 27% in a phase 3 trial [2], and donanemab has been reported to reduce decline in Integrated Alzheimer ’ s Disease Rating Scale by 32% in a phase 2 trial [3].”
MethodThe emerging era of staging Alzheimer’s disease pathology using plasma biomarkers
Mattsson, N., & Palmqvist, S. (2023) · Brain · doi:10.1093/brain/awad112 · Cited by 6
Functional and multi-omic aging rejuvenation with GLP-1R agonismPreprint
Huang, J., Kwok, A. J., Li, J. C. Y., Chiu, C. L. H., Ip, B. Y. M., Tung, L. Y., Zheng, X., Chow, H. T., Lo, M. P. S., Li, Z., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.06.592653 · Cited by 6
Eldik, L. J. V., Siemers, E., Collins, E. C., Gold, M., Henley, D. B., Johannsen, P., Möbius, H. J., Shulman, M. B., Zhou, J., Carrillo, M. C., et al. (2024) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70014 · Cited by 7
“2,4–6, 18 Due to their large study populations and collection of”
Development and Validation of a 18 F-Flortaucipir PET Visual Stratification Method
Tunali, I., Wang, J., Arora, A., Kim, M. J., Shcherbinin, S., Pontecorvo, M. J., & Iaccarino, L. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268700 · Cited by 5
“Inresearch settings and clinical trials, quantitation methods ( 13 – 17 ) have been used primarily to measure tau burden.”
Self-citationJapanese participant data from three gantenerumab trials in early Alzheimer's disease
Asada, T., Thanasopoulou, A., Delmar, P., Wojtowicz, J., Smith, J., Yoshiyama, Y., Yokoi, K., Watanabe, C., Isozaki, M., Ozaki, R., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70192 · Cited by 5
Frederiksen, K. S., Boada, M., Dubois, B., Engelborghs, S., Frisoni, G. B., Georges, J., Hort, J., Jönsson, L., Kramberger, M. G., Ousset, P., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01766-y · Cited by 13
“The findings from recent studies of anti-amyloid antibodies [5, 6, 22, 24–26] represent an inflection point in translating the understanding of AD pathophysiology to clinical practice.”
Life Purpose Lowers Risk for Cognitive Impairment in a United States Population-Based Cohort
Howard, N. C., Gerasimov, E. S., Wingo, T. S., & Wingo, A. P. (2025) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2025.05.009 · Cited by 8
O’Donnell, A. J., Fortunato, A. T., Spitznogle, B. L., Reddy, N. M., Kerper, S. A., & Handler, S. M. (2025) · Journal of the American Geriatrics Society · doi:10.1111/jgs.19577 · Cited by 7
“Recent advances in disease-modifying amyloid targeting therapies for AD demonstrate that older adults treated with either lecanemab or donanemab show moderately less decline on measures of cognition and function than placebo at 18 months [6–8].”
Li, H., Zhao, Z., Fassini, A., Lee, H. K., Green, R. J., & Gomperts, S. N. (2025) · Scientific Reports · doi:10.1038/s41598-025-05653-2 · Cited by 9
“…molecular weight Aβ protofibrils as well as fibrils in plaques) 2 , Donanemab (targeting the pyroglutamate modification seen in Aβ fibrils in plaques) 3 , and Aducanumab (targeting Aβ fibrils in plaques) 4 for the treatment of AD heralds the beginning of a new era, with evidence to date…”
Network pharmacology to elucidate the role of phytotherapy in neurocognitive disorders
Barth, S., & Efferth, T. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157031 · Cited by 9
Liu, Y., Chen, S., Li, S., Pei, Z., Fan, S., & Guo, Y. (2025) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823251362444 · Cited by 9
From Better Diagnostics to Earlier Treatment: The Rapidly Evolving Alzheimer’s Disease Landscape
Bougea, A. M., Debasa‐Mouce, M., Gulkarov, S., Castro‐Mosquera, M., Reiss, A. B., & Ouro, A. (2025) · Medicina · doi:10.3390/medicina61081462 · Cited by 8
“Reduced plasma levels of pTau217 and GFAP were linked to altered brain amyloid plaques detected by PET [24].”
Ma, S., Ene, J., McGarraugh, C., Ma, S., Esmonde, C., Liu, Y., & Li, Y. (2025) · Bioengineering · doi:10.3390/bioengineering12090933 · Cited by 8
“…and degenerative diseases, including rheumatoid arthritis (NCT03691909) [2], cystic fibrosis (NCT02866721) [3], Alzheimer’s (NCT03367403) [4], stroke (NCT03356821) [5], host vs. graft (NCT00366145) [6], and cancer [7], due to their self-renewal, multilineage differentiation, and…”
Oura, T., Tatekawa, H., Takeda, A., Omori, A., Atsukawa, N., Matsushita, S., Horiuchi, D., Takita, H., Shimono, T., Ueda, D., et al. (2025) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.70118 · Cited by 7
“DMT can reduce plaque burden and slow further cognitive worsening but does not restore lost function, likely reflecting the fact that neuronal damage and clearance system deficits have already been well established [3, 5].”
Challenges and opportunities in nanotherapeutics targeted for central nervous system disorders
Yong, J. M., Hakobyan, K., Mahmud, S. A. Z., Johnson, D., Lee, J., Diwan, A. D., Gu, Z., Moalem‐Taylor, G., & Mao, G. (2025) · Nanoscale · doi:10.1039/d5nr02463c · Cited by 5
Scherlo, M., Höveler, A., Mann, M., Gerwert, G., Güldenhaupt, J., Gerwert, K. B., Rudack, T., & Kötting, C. (2025) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2025.10.018 · Cited by 5
“Today, Lecanemab [9] and Donanemab [10] are the best therapeutic antibodies for Alzheimer ’ s disease and are already available as approved drugs.”
Multivariate models using NULISAseq and plasma p‐tau217 for staging Alzheimer's disease
Doecke, J. D., Stage, E., Fowler, C. J., Doré, V., Boehm, N., Kleinert, C., Challagundla, M., Feizpour, A., Ward, L. D., Fripp, J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70793 · Cited by 6
“…Dementia Rating Global (CDR-G) scale score of 0.5–1 and a Mini-Mental State Examination (MMSE) between 20 and 28 to be eligible for an AD DMT, 2,3 the global scientific and medical communities have been searching for the most cost-effective and accurate blood test that aligns with the…”
InfluentialAbduljawad, A. A., Alkinani, K. B., Zaakan, A., AlGhamdi, A. S., Hamdoon, A. A. E., Alshanbari, B. H., Alshehri, A. A., Alluhaybi, B. B., Alqashi, S. O. I., & Abduljawad, R. A. (2025) · Pharmaceuticals · doi:10.3390/ph18111731 · Cited by 9
“This helps to hamper the disease progression and improve cognitive performance and behavioral outcomes [66].”
Yoon, J.-Y., Ha, H., Lee, H. W., Kim, S.-Y., Yu, Y. M., & Chun, H. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03413-2 · Cited by 7
Mapping Alzheimer's disease heterogeneity with molecular imaging biomarkers
Harput, E., Boccalini, C., Mathoux, G., Prior, J. O., Dardel, N. T., Jreige, M., & Garibotto, V. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70163 · Cited by 6
ApoE4 lowers the ptau217 threshold for tau aggregation and spread in an allele dose-dependent manner
Steward, A., Dewenter, A., Hirsch, F., Roemer, S. N., Zhu, Z., Dehsarvi, A., Biel, D., Klonowski, M., Frontzkowski, L. K., Palleis, C., et al. (2025) · Brain · doi:10.1093/brain/awaf463 · Cited by 6
Palani, R. S., Williams, C. G., Thacker, D., Silvers, R., Qian, F., Weinreb, P. H., Mueller, L. J., Linse, S. S., & Griffin, R. G. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2515673122 · Cited by 7
“This recognition has led to the development of monoclonal antibodies that selectively bind amyloid fibrils ( 31 ) and in the case of aggregated A β they include aducanumab ( 30 ), lecanemab ( 32 , 33 ), and donanemab ( 34 , 35 ).”
Advances in Alzheimer’s disease: mechanistic insights and therapeutic targets
Jia, Y.-J., Ge, Y., Li, B., Yang, Y., Chen, H., Liu, J., Guo, J., Yu, J., Ye, K., Wang, J., et al. (2026) · Science China Life Sciences · doi:10.1007/s11427-025-2991-7 · Cited by 6
“The FDA ’ s approval of monoclonal antibodies such as lecanemab, which has been shown to slow cognitive decline, and donanemab, which can halt disease progression in some patients, marks a significant step forward (Mintun et al., 2021; Sims et al., 2023; van Dyck et al., 2023).”
Zhang, B., Yu, X., & Zhang, X. (2026) · Neurological Sciences · doi:10.1007/s10072-026-08893-w · Cited by 6
“Amyloid-related imaging abnormali-ties—cerebral edema or effusions, largely asymptomatic— were observed with donanemab [72].”
InfluentialPan-neurodegeneration proteomics reveals disease subtypes and molecular signatures
Shrestha, H. K., Sun, H., Yarbro, J. M., Lee, D., Liu, D., Wang, E., McReynolds, M. G., Zhang, N., Xie, B., Yang, S., et al. (2026) · Cell · doi:10.1016/j.cell.2026.02.026 · Cited by 19
Merkel, J., Perneczky, R., Jessen, F., Frölich, L., Jansen, O., Peters, S., Berg, D., Schulz, J. B., & Bartsch, T. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-02022-7 · Cited by 5
Ceperognastat in Early Symptomatic Alzheimer Disease: A Randomized Clinical Trial
Fleisher, A., Munsie, L. M., Mancini, M., Cheng, Y., Guo, J., Nuthall, H. N., Svaldi, D. O., Kotari, V., Kielbasa, W., Hutton, M. L., et al. (2026) · JAMA · doi:10.1001/jama.2026.12768 · Cited by 7
Self-citationDecision making in clinical trials: Interim analyses, innovative design, and biomarkers
Welsh-Bohmer, K. A., Kerchner, G. A., Dhadda, S., Garcia, M., Miller, D. S., Natanegara, F., Rakêt, L. L., Robieson, W., Siemers, E., Carrillo, M. C., et al. (2023) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12421 · Cited by 4
“16 Because many individuals with AD pathology also have substantial vascular and other pathology, 17 it will likely also be necessary to quantify these pathologies.”
BackgroundmiR-3940-5p reduces amyloid β production via selectively targeting PSEN1
Qi, Y., Wang, X., & Guo, X. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1346978 · Cited by 6
“Clinical trials utilizing monoclonal antibody (Donanemab) to selectively remove A β have demonstrated significant reductions in cognitive and functional decline in patients of early-stage AD (Mintun et al., 2021).”
BackgroundOverview of approved psychiatric medications 2008-2023: A systematic review
IsHak, W. W., Totlani, J., Murphy, N., Renteria, S., Chang, T. Y., Abdelsalam, R., Salem, M., Meyer, A., Khan, R., Chandy, T., et al. (2024) · World Journal of Advanced Research and Reviews · doi:10.30574/wjarr.2024.21.3.0705 · Cited by 5
Effect of astaxanthin in type-2 diabetes -induced APPxhQC transgenic and NTG mice
Babalola, J. A., Stracke, A., Loeffler, T., Schilcher, I., Sideromenos, S., Flunkert, S., Neddens, J., Lignell, Å., Prokesch, M., Pazenboeck, U., et al. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.101959 · Cited by 5
“The bene fi t of the currently approved anti-amyloid monoclonal antibodies, Aducanumab and Lecanemab, is still discussed controver-sially, and they are reported to cause considerable side effects [56 e 59].”
BackgroundVolloch, V., & Rits‐Volloch, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116036 · Cited by 6
Tests of abnormal gaze behavior increase the accuracy of mild cognitive impairment assessments
Tamaru, Y., Matsushita, F., & Matsugi, A. (2024) · Scientific Reports · doi:10.1038/s41598-024-70657-3 · Cited by 9
Emerging Novel Therapeutic Approaches for the Treatment of Alzheimer’s Disease
Panwar, A., Khan, M. I. K., Kumar, R., Kumar, R., Kumar, S., & Kumar, A. (2024) · Advances in Alzheimer s Disease · doi:10.4236/aad.2024.133006 · Cited by 5
Boustani, M. A., Doty, E. G., Garrison, L. P., Smolen, L. J., Klein, T. M., Murphy, D. R., Spargo, D. J., Belger, M. A., & Johnston, J. A. (2024) · Neurology and Therapy · doi:10.1007/s40120-024-00649-y · Cited by 13
Alzheimer's disease drug development in an evolving therapeutic landscape
Weninger, S. C., Irizarry, M. C., Fleisher, A., León, T., Maruff, P. T., Miller, D. S., Assunção, S. S., Carrillo, M. C., & Weber, C. J. (2024) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70015 · Cited by 6
Crețu, O., Cocu, M., Popescu, E.-R., & Chiriță, R. (2024) · Bulletin of Integrative Psychiatry · doi:10.36219/bpi.2024.4.08 · Cited by 5
Primary Progressive Aphasias: Diagnosis and Treatment
Ortíz, G. G., González-Usigli, H., Nava-Escobar, E. R., Ramírez-Jirano, L. J., Mireles-Ramírez, M. A., Orozco-Barajas, M., Becerra-Solano, L. E., & Sánchez-González, V. (2025) · Brain Sciences · doi:10.3390/brainsci15030245 · Cited by 6
“Its potential to modify disease progression could help in identifying patients with an AD profile among those with PPA [60].”
Temnik, M., Rudyk, M. P., Balakin, A., Gurin, S., Dovbynchuk, T., Byshovets, R., Dziubenko, N., Tolstanova, G. M., & Skivka, L. M. (2025) · Scientific Reports · doi:10.1038/s41598-025-97830-6 · Cited by 6
“7–9 .”
Pistolesi, A., Tuniz, S., Luceri, C., Molli, A., Urru, M., Rocca, A. I. L., Tanturli, M., Cesaris, F. D., Buonvicino, D., & Chiarugi, A. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107818 · Cited by 5
Advancing Disability Equity in Neurology
Aravamuthan, B. R., Moretti, L., Cejas, D. M., Singhal, D., Hamilton, R. H., Mohile, N. A., & Iezzoni, L. I. (2025) · Neurology · doi:10.1212/wnl.0000000000213873 · Cited by 10
Mukherjee, S., Coyle, R. A., Dubois, C., Perez, K. A., McLean, C., Masters, C. L., & Roberts, B. R. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02914-2 · Cited by 9
“With the recent success in anti-Aβ immunotherapy [17, 50], that targets the disordered N-terminus region of Aβ, indicates that a detailed understanding of PTMs in this region should yield better diagnostics and therapeutics for AD.”
Prediction of Early Alzheimer Disease by Hippocampal Volume Changes under Machine Learning Algorithm
Shang, Q., Zhang, Q., Liu, X., & Zhu, L. (2022) · Computational and Mathematical Methods in Medicine · doi:10.1155/2022/3144035 · Cited by 5
“According to clinical dementia rating (CDR) [13] score and the diagnostic standards of American Diagnostic and Statistical Manual of Mental Disorders [14], all the patients were rolled into three groups, including cognitive function normal group (normal group), early mild cognitive impairment group (e-MCI group), and…”
MethodRetractedRuss, H., Mazzanti, M., Parsons, C. G., Riemann, K., Gebauer, A., & Rammes, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105794 · Cited by 7
“AβpE3 is a clinically relevant target for AD-like Aβ1-42 since the anti-AβpE3 antibody donanemab demonstrated clinical efficacy in AD patients in a recent Phase II study [33].”
BackgroundKainuma, M., Ouma, S., Kawakatsu, S., Iritani, O., Yamashita, K.-I., Ohara, T., Hirano, S., Suda, S., Hamano, T., Hieda, S., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.991982 · Cited by 8
“, 2012), but no clinical study of aducanumab or other antibody drugs that have been done in recent years on patients with mild AD have shown MCID in ADAS-Jcog exceeding 2 points (Doody et al., 2014; Honig et al., 2018; US Food and Drug Administration., 2020; Mintun et al., 2021), and no consensus has been reached on M…”
BackgroundModulation of the Activity of the Insulin-Degrading Enzyme by Aβ Peptides
Kemeh, M. M., & Lazo, N. D. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00384 · Cited by 6
Pathophysiology of Alzheimer’s disease revealed by chemical exchange saturation transfer MRI
Zhuang, C., Chen, B., Chen, Y., Zhang, X., & Wu, R. (2023) · Radiology Science · doi:10.15212/radsci-2023-0004 · Cited by 6
CITIES: Clinical trials with intercurrent events simulator
Wahab, A. H. A., Qu, Y., Michiels, H., Luo, J., Zhuang, R., McDaniel, D., Xi, D., Polverejan, E., Gilbert, S. A., Ruberg, S. J., et al. (2023) · Biometrical Journal · doi:10.1002/bimj.202200103 · Cited by 7
“1 in Mintun et al. (2021) and the parameters for the AE poisson process was populated using the reported tab.”
BackgroundMethodResultInfluentialPET Imaging in Dementia: Mini-Review and Canadian Perspective for Clinical Use
Juengling, F. D., Wuest, F. R., Schirrmacher, R., Abele, J. T., Thiel, A., Soucy, J., Camicioli, R. M., & Garibotto, V. (2024) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2024.31 · Cited by 6
“3 – 5 The clinical picture of cognitive disturbances alone does not allow identification of its underlying cause with adequate precision, and to differentiate, for example, a cognitive decline due to depression, from a neurodegenerative process.”
WhatNIs N-ough for MRI-Based Animal Neuroimaging?
Grandjean, J., Lake, E. M. R., Pagani, M., & Mandino, F. (2024) · eNeuro · doi:10.1523/eneuro.0531-23.2024 · Cited by 4
The role and mechanism of dapagliflozin in Alzheimer disease: A review
Chen, P., Liang, L., Dai, Y., & Hui, S. (2024) · Medicine · doi:10.1097/md.0000000000039687 · Cited by 7
“[8] Existing FDA-approved drugs, such as acetylcholinester-ase (AChE) inhibitors (donepezil and galantamine) and the N-methyl-D-aspartate receptor antagonist memantine, have shown efficacy in the treatment of mild-to-moderate cognitive impairment.”
BackgroundPET in neurotherapeutic discovery and development
Chassé, M., & Vasdev, N. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00498 · Cited by 6
Emmerson, J. T., Carmo, S. D., Lavagna, A., Huang, C., Wong, T. P., Martínez-Trujillo, J., & Cuello, A. C. (2024) · Acta Neuropathologica Communications · doi:10.1186/s40478-024-01901-0 · Cited by 5
The Current Role of Tau PET Imaging in Neurodegeneration
Vanderlinden, G., Vandenberghe, R. R., Vandenbulcke, M., & Laere, K. V. (2025) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2025.03.002 · Cited by 8
The Ups and Downs of Amyloid in Alzheimer's
Siemers, E., Aisen, P. S. S., & Carrillo, M. C. (2021) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2021.54 · Cited by 5
“Positive clinical data were also achieved for a Phase 2 trial of donanumab (17).”
BackgroundPetersen, R. C., Graf, A., Carrillo, M. C., & Weber, C. J. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12361 · Cited by 5
“” Themeeting addressed two fundamental questions: (1) What is the evidence regarding the relationship between amyloid beta and tau? and (2) What does the evidence show about how anti-beta amyloid therapies alter clinical function? The meeting opened with a series of presentations to lay the groundwork on what we know…”
Sensi, S. L., Russo, M., & Tiraboschi, P. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-85538-9.00015-8 · Cited by 7
Long noncoding RNA MEG3 activates neuronal necroptosis in Alzheimer’s diseasePreprint
Balusu, S., Horré, K., Thrupp, N., Snellinx, A., Serneels, L., Chrysidou, I., Arranz, A. M., Sierksma, A. S. R., Simrén, J., Karikari, T. K., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.18.480849 · Cited by 5
In vivo tau staging in Alzheimer’s disease
Therriault, J., Gauthier, S. G., & Rosa‐Neto, P. (2022) · Aging · doi:10.18632/aging.204293 · Cited by 5
Koutarapu, S., Ge, J., Dulewicz, M., Srikrishna, M., Szadziewska, A., Wood, J. I., Blennow, K., Zetterberg, H., Michno, W., Ryan, N. S., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.03.596890 · Cited by 5
“…2022; Rafii et al. 2022; Satlin et al. 2016; Swanson et al. 2021; EISAI 2022; van Dyck et al. 2023) as well as positive Phase III results for donanemab (Sims et al. 2023; Mintun et al. 2021), which both provide significant support of the amyloid cascade hypothesis (Hardy 1992; Hardy & Selkoe 2002).”
BackgroundAPP β-CTF triggers cell-autonomous synaptic toxicity independent of AβPreprint
Luo, M., Zhou, J., Sun, C., Chen, W., Fu, C., Si, C., Zhang, Y., Geng, Y., & Chen, Y. (2024) · eLife · doi:10.7554/elife.100968 · Cited by 5
Glycolysis-enhancing α1-adrenergic antagonists are neuroprotective in Alzheimer’s diseasePreprint
Zhang, Q., Schultz, J. L., Simmering, J. E., Kirkpatrick, B. Q., Weber, M. A., Skuodas, S., Hicks, T. P., Pierce, G., Laughlin, M. H., Bertolli, A. X., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.03.647018 · Cited by 5
Jaeger, J., Staats, K. A., Barnum, S., Pope, P., Kingery, L. R., Buitendyk, M., Cohen, S., Tansey, M. G., Tesi, R. J., & Barnum, C. J. (2025) · medRxiv · doi:10.1101/2025.09.24.25336496 · Cited by 5
“Donanemab demonstrates higher rates at 15.7%, 22.8%, and 40.6% across the same categories 33 , while aducanumab reports ARIA-E incidence ranging from 29.5% to 43.0% in APOE ε4 carriers depending on dose 34 .”
InfluentialMachine learning–enhanced screening funnel for clinical trials in Alzheimer's disease
Gladstein, S., Yang, L., Wooten, D., Huang, X., Comley, R. A., Guo, Q., & Initiative, T. A. D. N. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70084 · Cited by 5
“9 The rest of the SFRs are calculated directly from the data.”
Jih, K., Hsu, T., Fuh, J., Lee, T.-H., Lin, Y., Fang, S., Liao, Y., & Lee, Y. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01744-4 · Cited by 4
“Three drugs have been approved by the US FDA since 2021, namely Aducanumab, Lecanemab and Donanemab [47–49].”
Targeting together cholinesterases and serotonin reuptake against Alzheimer’s disease
Guiselin, T., Lecoutey, C., Rochais, C., & Dallemagne, P. (2025) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgaf041 · Cited by 6
Clinical Role of Brain PET in Alzheimer Disease in the Era of Disease-Modifying Therapies
Franceschi, A. M., Keir, G., Benzinger, T. L. S., Cogswell, P. M., Ali, F., Petrella, J. R., Prescott, J. W., Whitlow, C. T., Zaharchuk, G., Allen, J. W., et al. (2025) · American Journal of Neuroradiology · doi:10.3174/ajnr.a8738 · Cited by 6
Role of Monoclonal Antibodies in Alzheimer’s Disease: Successes, Failures, and Future Directions
Gupta, A., Pahal, S., Kumar, V., & Chaudhary, A. (2025) · Neurological Sciences · doi:10.1007/s10072-025-08456-5 · Cited by 5
“Notably, about 38% of participants were APOE ε4 homozygotes, a group at elevated risk for ARIA [ 38 ].”
Assessment of Biological Activity of Low Molecular Weight 1,4-Benzoquinone Derivatives
Bartolić, M., Matošević, A., Maraković, N., Novaković, I., Sladić, D. M., Žunec, S., Opsenica, D., & Bosak, A. (2025) · Biomolecules · doi:10.3390/biom15081162 · Cited by 4
“These monoclonal antibodies target aggregated β -amyloid, aiming to reduce amyloid plaque burden and slow cognitive decline [17,18].”
Ramachandran, A. K., Govindula, A., Ranadive, N., Birangal, S., Bhat, V. G., Fayaz, S. M., Shenoy, G. G., & Mudgal, J. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178192 · Cited by 5
Chan, I., Maruff, P. T., Pietrzak, R. H., Perin, S., & Lim, Y. Y. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120504 · Cited by 6
The association of the Wnt/β-catenin signaling pathway with Alzheimer's disease
Ma, J., Liu, Y., Lu, D., & Sun, Q. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110754 · Cited by 5
Duncan, G. B., Dickson, S. P., Kaplan, J. M., Johnson, S. B., Duke, T. M., Dayley, C. W., Hendrix, S. B., Altstiel, L. D., & Mallinckrodt, C. H. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70183 · Cited by 5
de Souza, P. C., Bezerra, T. P. W., Rêgo, M. J. B. D. M., & da Rosa, M. M. (2025) · The American Journal of Medicine · doi:10.1016/j.amjmed.2025.11.025 · Cited by 8
Ren, S., Singh, J., Gsteiger, S., Cogley, C., Reed, B., Abrams, K. R., Dawoud, D., Owen, R. K., Tappenden, P., Quinn, T. J., et al. (2025) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2025-0095 · Cited by 7
“This research has culminated in the completion of a number of randomized controlled trials (RCTs) assessing anti-A β drugs, including: aducanumab [1] ; lecanemab [2] ; donanemab [3] and gantenerumab [4] , which vary in their mechanism of action.”
Metadata
- Authors
- Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., Apostolova, L. G., Salloway, S. P., & Skovronsky, D. M.
- Affiliations
- Eli Lilly (United States) (US)
- From Eli Lilly (M.A.M., A.C.L., C.D.E., A.M.W., P.A.A., S.W.A., S.S., J.S., J.R.S., M.B., D.M.S.) and the Departments of Neurology, of Radiology and Imaging Sciences, and of Medical and Molecular Genetics and the Indiana Alzheimer Disease Center, Indiana University School of Medicine (L.G.A.) — both in Indianapolis; and the Departments of Psychiatry and Human Behavior and of Neurology, Butler Hospital, Warren Alpert Medical School of Brown University, Providence, RI (S.P.S.).
- Brown University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-05-06
- Volume
- 384
- Issue
- 18
- Pages
- 1691-1704
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3137826907
- Cited by
- 1,728
- References
- 39
- Citations by year
- 2026: 302 · 2025: 409 · 2024: 369 · 2023: 271 · 2022: 263 · 2021: 112
- FWCI
- 160.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- donanemab, early Alzheimer's disease, amyloid-beta, anti-amyloid antibodies, amyloid plaques, tau burden, activities of daily living, cognitive decline
- MeSH terms
- Mental Status and Dementia Tests, Activities of Daily Living, Aged, Alzheimer Disease, Epitopes, Brain Edema, Cognition, Double-Blind Method, Female, Humans, Male, Pyrrolidonecarboxylic Acid, Severity of Illness Index, Disease Progression, Plaque, Amyloid, Administration, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.